

Appendix to:**Title:**

Type-Specific Concurrent Anogenital HPV Detection among Young Women and MSM attending Dutch Sexual Health Clinics.

Authors:

Johannes M.A. Kusters^{1,2}

Janneke C.M. Heijne¹

Birgit H.B. van Benthem¹

Audrey J. King¹

Maarten F. Schim van der Loeff^{2,3}

¹*Centre for Infectious Diseases Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands*

²*Institute for Infection and Immunity (AII), Amsterdam UMC, Amsterdam, the Netherlands*

³*Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands*


Supplementary Table 1: Type-specific prevalence for genital, anal and concurrent detected HPV infection, young women and MSM recruited at sexual health clinics in 2009 - 2019 in the Netherlands

HPV type	Women (n=1,492)			MSM (n=614)		
	Genital infection ¹ n (%)	Anal infection ² n (%)	Concurrent infection n (%)	Genital infection ¹ n (%)	Anal infection ² n (%)	Concurrent infection n (%)
Any type-specific ³	1,149 (77.0)	693 (46.5)	607 (40.7)	194 (31.6)	301 (49.0)	64 (10.4)
High risk types						
HPV 16	122 (8.2)	57 (3.9)	46 (3.1)	21 (3.4)	55 (9.0)	7 (1.1)
HPV 18	67 (4.5)	33 (2.2)	21 (1.4)	21 (3.4)	46 (7.5)	8 (1.3)
HPV 31	139 (9.3)	65 (4.4)	45 (3.0)	12 (2.0)	35 (5.7)	3 (0.5)
HPV 33	60 (4.0)	34 (2.3)	22 (1.5)	6 (1.0)	19 (3.1)	0 (0.0)
HPV 35	39 (2.6)	31 (2.1)	19 (1.3)	4 (0.7)	14 (2.3)	1 (0.2)
HPV 39	129 (8.7)	64 (4.3)	46 (3.1)	9 (1.5)	17 (2.8)	1 (0.2)
HPV 45	39 (2.6)	20 (1.3)	13 (0.9)	9 (1.5)	16 (2.6)	4 (0.7)
HPV 51	355 (23.8)	198 (13.3)	159 (10.7)	31 (5.1)	56 (9.1)	9 (1.5)
HPV 52	288 (19.3)	160 (10.7)	131 (8.8)	18 (2.9)	40 (6.5)	7 (1.1)
HPV 56	176 (11.8)	102 (6.8)	77 (5.2)	12 (2.0)	23 (3.8)	2 (0.3)
HPV 58	63 (4.2)	30 (2.0)	24 (1.6)	2 (0.3)	6 (1.0)	0 (0.0)
HPV 59	72 (4.8)	33 (2.2)	20 (1.3)	5 (0.8)	15 (2.4)	0 (0.0)
Low risk types						
HPV 6	183 (12.3)	148 (9.9)	107 (7.2)	43 (7.0)	80 (13.0)	17 (2.8)
HPV 11	31 (2.1)	14 (0.9)	13 (0.9)	22 (3.6)	48 (7.8)	13 (2.1)
HPV 34	18 (1.2)	5 (0.3)	2 (0.1)	1 (0.2)	2 (0.3)	0 (0.0)
HPV 40	39 (2.6)	23 (1.5)	13 (0.9)	5 (0.8)	11 (1.8)	0 (0.0)
HPV 42	27 (1.8)	6 (0.4)	2 (0.1)	1 (0.2)	1 (0.2)	0 (0.0)
HPV 43	60 (4.0)	38 (2.6)	24 (1.6)	16 (2.6)	10 (1.6)	2 (0.3)
HPV 44	50 (3.4)	31 (2.1)	24 (1.6)	9 (1.5)	10 (1.6)	0 (0.0)
HPV 53	259 (17.4)	155 (10.4)	115 (7.7)	13 (2.1)	33 (5.4)	3 (0.5)
HPV 54	121 (8.1)	51 (3.4)	29 (1.9)	12 (2.0)	10 (1.6)	0 (0.0)
HPV 66	223 (15.0)	127 (8.5)	99 (6.6)	23 (3.8)	37 (6.0)	8 (1.3)
HPV 68	79 (5.3)	35 (2.4)	24 (1.6)	11 (1.8)	18 (2.9)	3 (0.5)
HPV 70	27 (1.8)	11 (0.7)	6 (0.4)	2 (0.3)	6 (1.0)	0 (0.0)
HPV 74	65 (4.4)	35 (2.4)	23 (1.5)	5 (0.8)	17 (2.8)	1 (0.2)

Note: The analyses are based on 1,492 women and 614 MSM with genital and anal samples collected in 2009, 2011, 2013, 2015, 2017 or 2019.

1. Irrespective of anal HPV infection.
2. Irrespective of genital HPV infection.
3. Positive for at least one genotype.

Abbreviations: HPV = human papillomavirus, MSM = men who have sex with men.



Supplementary Figure 2: Flowchart with the overview of number of participants or records per analysis for calculation of the concordance between anogenital sites and assessing risk factors for concurrent anogenital detection among women recruited at sexual health clinics in the Netherlands, 2009-2019